Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

788.19 -1.13 (-0.14%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Summer 2024 Snapshot Of The S&P 500's Market Cap
The market capitalization of the S&P 500 grew by 4.2% during the course of the second quarter of 2024. The index ended 2024-Q2 with a market cap of $47.83 trillion according to Standard and Poor. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases. 
Via InvestorPlace
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
No matter how you look at it, the FDA approval of Kisunla is big for Eli Lilly. 
Via The Motley Fool
Exposures Product Safety
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE: LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know. 
Via Benzinga
Smart Money Is Betting Big In LLY Options
Via Benzinga
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
The CNN Money Fear and Greed index slightly decreased, remaining in Neutral zone. US stocks mixed, with S&P 500 at record high. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic. 
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Patients lost more more weight on Mounjaro than Ozempic. 
Via Investor's Business Daily
A $2.5 Trillion Opportunity In The Biotech Industry
In 1979, Genentech managed to create synthetic human insulin. Now 45 years later, biotech is a $1.77 trillion industry — up from $1.55 trillion in 2023. By 2030, that’s projected to reach close to $4... 
Via Talk Markets
Facebook Parent Meta Platforms Among 4 Hot Stocks At All-Time Highs: Look For The Best Stocks On These IBD Lists
Meta Platforms came aboard the Big Cap Leaders list, as did medical standout Eli Lilly. They were among four stock at all-time highs Monday. 
Via Investor's Business Daily
Gold Falls Over 1%; HilleVax Shares Plunge
Via Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace
Dow Turns Lower; Myomo Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market News From Amazon, Nike, McCormick, and More
We also talk with author Nicola Twilley about her new book, "Frostbite: How Refrigeration Changed Our Food, Our Planet, and Ourselves." 
Via The Motley Fool
Why Is Morphic (MORF) Stock Up 75% Today?
Morphic stock is up on Monday after the company signed a deal with Eli Lilly for the acquisition of MORF shares at $57 each in cash. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Eli Lilly to acquire Morphic Holding Inc for $3.2 billion, strengthening its portfolio in chronic disease treatments. Morphic's lead program, MORF-057, targets inflammatory bowel disease, with... 
Via Benzinga
Eli Lilly Snaps Up Morphic At 79% Premium
Eli Lilly said Monday it would pay $3.2 billion to acquire an innovator in oral treatments for chronic bowel diseases. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy in July
Investors shouldn't have to think too hard about these great stocks. 
Via The Motley Fool
The Next $1 Trillion Stock? Tesla, Warren Buffett's Berkshire Hathaway In The Running
Tesla, Warren Buffett's Berkshire Hathaway are close, but this is No.1. 
Via Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Southern Copper and Agnico Eagle surged above early entries. 
Via Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce the risk of ten obesity-related cancers in type 2 diabetes patients, highlighting... 
Via Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
However, small caps fell. Cooling economic data raised rate-cut hopes. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
Could Zealand Pharma be a better option for growth-oriented investors? 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.